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Levetiracetam is a new anti-convulsant with impressive pivotal trial credentials. We examined its effectiveness in refractory
clinic patients with epilepsy with a year’s follow up. Six months after initiation 32% of the patients were seizure free, and 26%
at one year.
By the end of the 12 months follow up 77% of patients were still taking the drug, having gained benefit from it: 23% had
dropped out due to intolerable side effects, seizure increase or lack of efficacy. There is evidence that the drug is broad spectrum
and as effective in primary generalised epilepsy as in partial onset epilepsy. Our audit of its use and effectiveness has led us to
position it as our first choice add-on drug if the initial monotherapy drug fails.
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INTRODUCTION
The aim of epilepsy care is to render people with
the condition seizure free—it is only seizure freedom
that saves lives and prevents sudden death in epilepsy.
Seizure freedom also brings improvement in morbid-
ity and in quality of life. Unfortunately clinical trials
of new antiepileptic drugs concentrate on measuring
50% reductions in seizure frequency (admirable but
of little use to the patient) and also are short term,
not usually longer than 18–20 weeks. Clinical trials
therefore concentrate on short-term improvement and
side effects and tell us very little else (and are de-
signed purely to get the drug to the market). There is a
need, therefore, to explore the use, benefits and draw-
backs of antiepileptic drugs once they have reached
the market. We present the results of a year’s follow
up of a new anti-convulsant drug, Levetiracetam, in a
clinical setting, measuring the number of patients that
became seizure free and those that remained seizure
free, the number of patients who did not gain benefit
(or only limited benefit) from the drug and whether
any positive gains from the drug were only short-term,
or whether they lasted.
Patients usually enrolled in clinical trials in the
UK are pharmaco-resistant anyway, since they have
usually been exposed to most of the existing anti-
convulsant drugs. An audit of a drug’s clinical use
may give a clearer picture of those patients that may
respond to the new drug. Once a drug is licensed it
also becomes the clinician’s responsibility whether to
use it strictly within the licence or whether its use can
be extended out of the licence to types of epilepsy
not currently covered by it. This has always been our
policy. In judging the effect of a new drug in a clinic
it also has to be remembered that the first drug tried
in the patient is the one most likely to work, if chosen
correctly, and there is a law of diminishing return as
other drugs are tried. After successive failures with
other drugs, there is a diminishing likelihood that
the patient will become seizure free1, 2. A drug that
does create seizure freedom in a substantial propor-
tion of pharmaco-resistant patients, which is then
maintained, would be very valuable in a clinic popu-
lation where disappointment with new medication is
the rule.
Levetiracetam is the S-enantioner of a pyrrolidone
derivative and is structurally similar to Piracetam, a
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drug used in the UK for resistant myoclonic seizures.
Interestingly Levetiracetam failed the usual animal
screening tests for antiepileptic activity but has been
shown in other pre-clinical tests to be a powerful
anti-convulsant with some evidence of neuroprotec-
tion and seems active against animal models of both
partial and generalised epilepsy3.
Although the drug has a unique specific binding
site in the brain4, its mode of action is unknown.
It certainly appears to have no effect on GABA or
sodium transport mechanisms and is therefore dif-
ferent from most antiepileptic drugs. Animal studies
have shown little acute or chronic toxicity and no ev-
idence of teratogenesis. In man there is rapid absorp-
tion after oral ingestion, steady state is reached in
48 hours, it has linear kinetics and only 10% plasma
protein binding and is renally excreted. There ap-
pear to be no drug interactions; twice daily dosage
is acceptable because brain retention is much longer
than its rather short half-life. It has a fairly unique
pharmaco-kinetic profile and theoretically should be
easy to use5.
There have been three pivotal double-blind placebo
controlled trials, which showed a definite dose–
response curve in seizure control significantly superior
to the placebo. A total of 8% of patients receiving the
higher dose of Levetiracetam (3 g total daily dose) be-
came seizure free. Simple partial, complex partial and
secondary generalised seizures all showed a signifi-
cant response to Levetiracetam with a rapid and sus-
tained clinical improvement over the fairly short term
of the trials6. Would the apparent ease of use and im-
pressive efficacy in double-blind controlled trials hold
up in actual clinical practice? A study of the long-term
continuation (retention) rate, efficacy and safety data
was made of all patients with epilepsy exposed to the
drug during its developmental program7. The reten-
tion rate in this study was 60% after 1 year and 32%
after 5 years: 13% of patients became seizure free for
at least 6 months. We decided to examine the seizure
freedom and retention rate in a population of patients
in our clinic, with mixed epilepsy diagnoses, given
the drug and followed for a year. We also looked at
the drop out rate and the reason why patients dropped
out.
METHOD
Levetiracetam became available for clinical use in
the UK in October 2000 with a licence restrict-
ing its use to resistant partial onset epilepsy with
or without secondary generalisation. However we
extended its use (because of previous clinical expe-
rience) to patients with resistant primary generalised
epilepsy.
RESULTS
The records of 120 patients with resistant epilepsy,
either partial onset or primary generalised, who were
offered the drug in our clinic, between October 2000
and August 2001 were scrutinised. A note was made of
diagnosis and seizure frequency before Levetiracetam
was added, reduction in seizure frequency at 6 and 12
months after the introduction of Levetiracetam, side
effects, whether the patient was still taking the drug
at 6 and 12 months (and if not what the reason was
for withdrawal) and maximum dosage used at 6 and
12 months.
One hundred and twenty patients came into ascer-
tainment but, for reasons that were unclear, one pa-
tient, though slated to receive Levetiracetam, never
started on it. One patient dropped out after only two
doses but is included in the audit: 119 patients are
therefore included in the results.
Fig. 1 shows changes in seizure frequency at 6
months and at 1 year for the whole group as a per-
centage, divided into epilepsy types. Of the group as
a whole 32% were seizure free at 6 months and 26%
were seizure free at 1 year.
Fig. 2 shows those patients withdrawing from Lev-
etiracetam at 6 and 12 months. Twenty-one patients
had withdrawn by 6 months (two with more than one
reason) and 27 patients had withdrawn by 1 year (one
with multiple reasons). The intolerable side effects (at
6 and 12 months), which had lead to patient with-
drawal, are shown in Table 1. Ninety-eight patients
were still taking the drug at 6 months, although some
had side effects that they felt were tolerable; these are
shown in Table 2. Ninety-two patients were still tak-
ing Levetiracetam at the end of 12 months.
Table 1: Intolerable side effects (n=14).
At 6 months At 12 months
Tiredness 3 4
Depression 2 2
Ataxia 4 4
Aggression 3 4
Insomnia 3 4
Nausea 2 2
Some patients had more than one side effect.
Table 2: Tolerable side effects in patients remaining at 6
months (n=98).
Tiredness 22
Poor memory 1
Ataxia 2
Aggression 1
Insomnia 1
Nausea 1
Weight gain 2
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Fig. 1: Seizure frequency in patients taking Levetiracetam over 1 year (n=119). One subject withdrew after taking two doses,
so no seizure frequency was recorded.
Fig. 2: Patients withdrawing Levetiracetam over 1 year (n=119): reason for withdrawal. Twenty-one patients withdrew by 6
months (two with >1 reason). Twenty-seven patients withdrew by 12 months (one with >1 reason).
Table 3: Mean dose taken by seizure free patients.
Epilepsy type n Mean dose (mg) at 6 months n Mean dose (mg) at 12 months
Partial onset 25 1800 ± 816.50 22 2295 ± 750.54
Generalised 13 2154 ± 473.67 9 1944 ± 463.98
Totals 38 1921 ± 730.85 31 2194 ± 691.34
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Table 4: Seizure frequency after 12 months for patients
seizure free at 6 months (n=38).
Seizure frequency after 12 months
↓ to same as before Levetiracetam 1 (3%)a
↓ to 50% reduction compared to
before Levetiracetam
2 (5%)b
↓ to 90% reduction compared to
before Levetiracetam
7 (18%)c
Remained seizure free 28 (74%)
a Seizure control lost when LTG reduced. b Levetiracetam
withdrawn due to side effects (1); unexplained reduction in
seizure frequency (1). c Increase in seizures when CLN
withdrawn (1); increase in seizures when CBZ withdrawn (2);
increase in seizures when VPA withdrawn (1); due to stress (1);
unexplained reduction in seizure frequency (2).
Table 5: Seizure frequency after 12 months for patients not
seizure free at 6 months (n=60).
Seizure frequency at 12 months (compared to 6 months, %)
Worse 5
Same 49a
Better 6b
a But NOT seizure free. b Three became seizure free.
Table 3 shows the mean dose of Levetiracetam given
to patients who were seizure free at 6 months and at 1
year. Tables 4 and 5 examine those patients who were
seizure free at 6 months and whether they were still
seizure free at 12 months and if not, possible reasons
for return of seizures. Most seem to lose their seizure
control when concomitant medication was withdrawn,
although one patient had to withdraw from Levetirac-
etam, even though he had achieved seizure control
with it, because of side effects, which he felt were
intolerable.
Of the 98 patients who continued with Levetirac-
etam beyond 6 months, 60 at that time were not seizure
free. Most retained the same degree of seizure con-
trol as they had had at 6 and 12 months but were not
seizure free. Six had better control than at 6 months
(of whom three at 12 months were now seizure free).
Five patients had worse seizure control at 12 months
than they had had at 6 months and are in the process
of withdrawing from the drug.
DISCUSSION
All of these patients, as would be expected with the in-
troduction of a new antiepileptic drug, can be classed
as being fairly resistant to medication. All of the par-
tial onset seizure patients had tried at least four other
antiepileptic drugs before Levetiracetam was insti-
tuted and most were on two antiepileptic drugs at
the time Levetiracetam was given to them. The pri-
mary generalised group had all failed to gain con-
trol with at least Sodium Valproate, Lamotrigine and
a Benzodiazepine: many had taken other drugs as
well.
The initial seizure freedom rate is therefore, in this
group of refractory patients, surprising. Although
there is not a 100% retention rate at 12 months, in
terms of seizure freedom, 74% of the patients who
were seizure free at 6 months remained seizure free
at 12 months. A small number of patients, who were
not seizure free at 6 months have become seizure free
by 12 months. Overall, in terms of the total group
who started to take Levetiracetam, 26% have been
seizure free for a year and are therefore eligible for
a driving licence, have an improved quality of life,
and, of course, are free of the risk of sudden death in
epilepsy, which is high in this population of patients
with refractory epilepsy.
We intend to follow this group of patients to see if
this retention rate is maintained and enlarge our ex-
perience of how to use this drug. Like most clinicians
we now tend to start it with a lower starting dose and
a slower increment in dosage than currently recom-
mended by the manufacturers. This, in itself, may
reduce the small number of patients who drop out
because of intolerable side effects. Our data suggests
that the clinician will learn fairly quickly whether the
drug had been effective or not, and, if it is effective,
that effectiveness will tend to stay for at least a year.
We are also continuing to audit our use of the drug
outwith its current license, particularly in Juvenile
Myoclonic Epilepsy and photo and pattern sensitivity,
for which it seems extremely effective8, 9.
Our initial experience with this drug is favourable.
Because of its impressive and sustainable seizure free-
dom rate, its comparatively low side effect profile and
its lack of interactions with other medication plus the
finding from this audit that one knows pretty quickly
whether it is going to be effective or not, in our clinic
we have positioned it as the rational first add on drug
if the initial monotherapy drug fails. Formal trials in
primary generalised epilepsy, photo and pattern sen-
sitivity and as an initial monotherapy drug are clearly
very necessary.
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